The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable excitement within the industry. A shift away from Schedule I status, often viewed as outdated and hindering https://livebackpage.com/story6216569/cannabinoid-rescheduling-a-growth-catalyst